Nguy cơ biến chứng tim mạch ở người hút thuốc lá lâu năm rất cao, kể cả ở người trẻ dưới 40 tuổi. Theo bác sĩ, hút thuốc là một trong những yếu tố chính gây nhồi máu cơ tim, đột quỵ ngoài bệnh nền và yếu tố bẩm sinh. Bảo vệ sức khỏe tim mạch bằng cách từ bỏ thuốc lá là cần thiết và cấp bách.
#TimMach #HutThuocLa #NhomiMacCoTim #DotQuy #Suckhoe #HeartHealth #Smoking #CardiovascularRisk #VietnameseHealth
https://vietnamnet.vn/nguy-co-bien-chung-tim-mach-o-nhung-nguoi-hut-thuoc-la-lau-nam-2463602
The Impact of Poor Mental Health on Cardiovascular Risk in Young Adults
Explore how poor mental health elevates cardiovascular disease risk in young adults. Understand the science, learn prevention strategies, and take control of your heart health.
https://www.chumsay.com/read-blog/104750_the-impact-of-poor-mental-health-on-cardiovascular-risk-in-young-adults.html
#MentalHealth #HeartHealth #YoungAdults #CardiovascularRisk #StressManagement #Wellness #Anxiety #Depression
📄 'Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials' - an article in the #KargerPublishers research collection on #ScienceOpen:
🔎🔗 https://www.scienceopen.com/document?vid=ac8b97db-bc83-4f86-ad4b-32df11bfa6d3
#PlaquePsoriasis #Guselkumab #SystemicInflammation #CardioDerm #IL23Inhibitor #CardiovascularRisk
<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d7357805e237"> <b> <i>Introduction:</i> </b> Psoriasis is associated with an increased risk of cardiovascular disease (CVD). Previous studies have found that treatment with tumour necrosis factor or interleukin (IL)-17 inhibitors leads to reductions in the systemic inflammation biomarkers neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and monocyte/lymphocyte ratio (MLR). The primary aim of this study was to evaluate changes in NLR, PLR and MLR with guselkumab compared with placebo (VOYAGE I/II), adalimumab (VOYAGE I/II), and secukinumab (ECLIPSE). The secondary aims were to assess correlation with disease severity, C-reactive protein (CRP) levels, and treatment response. <b> <i>Methods:</i> </b> This was a post hoc analysis of VOYAGE I, VOYAGE II, and ECLIPSE Phase III randomised trial data on guselkumab for moderate-to-severe plaque psoriasis. NLR, PLR, and MLR were evaluated at baseline and Week 16 in VOYAGE I and II and at baseline and Week 12 in ECLIPSE. Mean changes were compared between groups using a Student’s <i>t</i> test; Pearson’s test was used for correlation analyses. <b> <i>Results:</i> </b> VOYAGE I included 837 randomised patients, VOYAGE II included 992 randomised patients, and ECLIPSE included 1,048 randomised patients. In VOYAGE I, NLR ( <i>p</i> = 0.011), PLR ( <i>p</i> = 0.015), and MLR ( <i>p</i> = 0.004) decreased significantly following 16 weeks of guselkumab treatment vs. placebo. In VOYAGE II, reductions in NLR ( <i>p</i> = 0.003), PLR ( <i>p</i> = 0.006), and MLR ( <i>p</i> = 0.001) were greater at Week 16 in patients treated with guselkumab vs. placebo. Treatment with adalimumab was associated with a greater reduction ( <i>p</i> < 0.001) in the three biomarkers vs. guselkumab, while secukinumab resulted in a similar reduction in NLR, PLR, and MLR compared with guselkumab ( <i>p</i> = 0.413, 0.650, and 0.498, respectively). All biomarkers weakly correlated with Psoriasis Area and Severity Index (PASI) at baseline and showed modest correlations with CRP levels. Biomarkers in patients who were PASI90 responders were consistent between all active treatment groups at baseline. <b> <i>Conclusions:</i> </b> Guselkumab is a highly efficacious treatment for plaque psoriasis; the study has demonstrated the potential benefit of treatment with guselkumab in reducing systemic inflammation as measured by NLR, PLR, and MLR, which appeared to be independent of psoriasis response, suggesting that reducing systemic inflammation with guselkumab may decrease CVD risk. </p>
You walk into the clinic, maybe feeling a little rushed, a little anxious. It’s appointment time. The nurse wraps the cuff around your arm, it tightens, and then… the numbers. #ambulatorybloodpressuremonitoring #anxiety #cardiovascularrisk #highbloodpressure #homebloodpressuremonitoring #hypertension #whitecoatsyndrome
You walk into the clinic, maybe feeling a little rushed, a little anxious. It’s appointment time. The nurse wraps the cuff around your arm, it tightens, and then… the numbers. #ambulatorybloodpressuremonitoring #anxiety #cardiovascularrisk #highbloodpressure #homebloodpressuremonitoring #hypertension #whitecoatsyndrome
Nuevo #MetaAnálisis sobre los riesgos a la salud por consumir #cannabis: 29% de incremento de riesgo de angina/#infarto del miocardio, 20% de incremento en el riesgo de #stroke/#ictus y se duplica el riesgo de #Muerte por problemas cardiovasculares.
🤷🏽♂️ #CardiovascularRisk #EVC #Toulouse #Strasbourg #Heart #BMJ
https://heart.bmj.com/content/early/2025/06/10/heartjnl-2024-325429
Background Awareness has recently risen about the potential associated risks to the cardiovascular health of cannabis users. The objective was to evaluate the possible association between major adverse cardiovascular events (MACE) and the use of cannabis or cannabinoids. Methods Original pharmacoepidemiological studies providing risk estimates on cannabis-related MACE (ie, cardiovascular death, non-fatal acute coronary syndrome (ACS) including myocardial infarction (MI) or non-fatal stroke) published from 1 January 2016 to 31 January 2023 were included in the systematic review exploring PubMed, Web of Science and Scopus (last search: 20 September 2023). Design, duration, baseline characteristics, exposure, inclusion criteria, sample size, effect size and confusing factors, including exposure to psychoactive substances, were extracted. Study quality was assessed using the ROBINS-E (risk of bias in non-randomised studies—of exposures) tool. In the meta-analysis, adjusted effect estimates and their 95% CIs were pooled using a DerSimonian and Laird random effect model with inverse variance weighting based on the type of outcome (PROSPERO: CRD42023401401). Results Overall, 24 articles were included from 3012 initial records, including 17 cross-sectional studies, 6 cohort studies and 1 case-control study. Exposure corresponded to the use of cannabis in all studies, with one focused on medical cannabis. The estimated risk ratio (RR) was 1.29 (95% CI 1.05 to 1.59) for ACS, 1.20 (1.13 to 1.26) for stroke and 2.10 (1.29 to 3.42) for cardiovascular death. As measured in two studies, no statistically significant association was found for the composite outcome combining ACS and stroke. The focused analysis restricted to cohort studies yielded comparable results to the primary model (RR=1.32, 1.01 to 1.73). Conclusions This systematic review and meta-analysis uses an original approach centred on real-world data. The findings reveal positive associations between cannabis use and MACE. These findings should encourage investigating cannabis use in all patients presenting with serious cardiovascular disorders. PROSPERO registration number CRD42023401401. No data are available. The data explored in this systematic review and meta-analysis have been extracted from publicly available databases. Although the authors will not share the data directly, any interested researcher may apply the search strategy developed for this analysis, available in the online supplemental appendix.
Late-onset type 1 diabetes isn’t milder — it’s just as deadly if unmanaged. New research calls for urgent action. #Type1Diabetes #CardiovascularRisk #HealthData
https://geekoo.news/later-life-type-1-diabetes-carries-heavy-heart-risk/
Nuevo índice/#biomarcador de #RiesgoCardiovascular en pacientes con #SíndromeMetabólico.
El #TyG (índice Triglicéridos y Glucosa) menor a 9 tiene un valor predictivo negativo de 89% para riesgo intermedio/alto de eventos cardiovasculares en los siguientes 10 años.
Y es relativamente barato y fácil de aplicar.
#Biomarker #MetabolicSyndrome #PreDiabetes #CardiovascularRisk #Health
Vietnamnet BOT
MrMed : Online Pharmacy
Newsramp
ScienceOpen
Dr Priya Sammani ( MBBS ,DFM )
Geekoo
Yonhap Infomax News
